In partnership with
Scale AI support on AWS, see how July 9
Customer expectations keep rising. Support budgets don't. On July 9, Fin and AWS are hosting a live executive session on how leading enterprises close that gap: scaling AI-powered support while simplifying how they buy it.
You'll see how to resolve an average 76% of conversations with Fin on AWS enterprise-grade infrastructure, procure through AWS Marketplace to put committed cloud spend to work, and turn the Fin and AWS collaboration into lower support costs. Register for the live session to see how.
Pills in a blister pack. The drug is the easy part. The chemistry behind it is the hard part. Photo: Wikimedia Commons (CC0).
If a pharmacist has told you your medication is "on backorder" lately, you are not imagining it. In the first quarter of 2024, American pharmacists were juggling 323 active drug shortages at once, the most since tracking began in 2001, just past the old 2014 record of 320 (the count comes from ASHP and the University of Utah).
Here is the part that does not make the news. The drugs running short are mostly not the ones with TV ads. Almost half of the new 2024 shortages were generic sterile injectables: chemotherapy, anesthetics, the emergency drugs on a hospital crash cart. Cheap, old, low-margin medicines that a handful of plants make for the whole country. When one line goes down, no second supplier is waiting.
Why a cheap drug disappears
The economics explain almost everything. A generic injectable can sell for about a dollar a vial. There is no money in it, so there are few makers, often one or two, frequently overseas, running old plants flat out. One contaminated line or a failed inspection, and a national shortage follows weeks later. The same logic drives the Adderall shortage, which began in October 2022 and still has not fully cleared in 2026 even after regulators lifted manufacturing quotas. Some strengths fill fine; others vanish for weeks and reappear without warning. Not every scare lasts: the Ozempic and Wegovy shortage that defined 2023 was declared resolved by the FDA in February 2025. The lesson it left was not about one drug. It was about how little slack the system carries.
The value chain, and the part you never see
Follow a generic pill backward and the trail leaves the country fast. India is the pharmacy of the world, the largest single source of America's generics and the ingredients inside them, with Europe supplying much of the rest. On the surface China looks minor, only about 8 percent of US active ingredients by volume. But that number hides the real dependence. India does not make most of its own raw chemistry; it buys roughly 70 percent of those starting materials from China. So the chain that looks like it runs through Mumbai actually begins one step further upstream, in Chinese chemical plants. Count that indirect exposure and reliance on China climbs toward half. China is not the name on the label. It is the supplier behind the supplier, which is far harder to replace in a hurry. Together, China and India are close to 58 percent of US drug imports by weight.
The half-trillion-dollar answer
Washington noticed, and tariffs did the rest. After the 2025 trade measures, including a doubling of duties on Chinese goods, the money started moving. Eli Lilly committed 27 billion dollars to US manufacturing in 2025, three sites of it for active ingredients. Novo Nordisk added about 9 billion. All told, 14 drugmakers have announced more than 480 billion dollars of US production over the next four to ten years. It is a real shift, but read the timeline before you exhale. Bringing raw-ingredient chemistry home is a multi-year build, and that cheapest, dirtiest step is the hardest to reshore because nobody wanted it here in the first place. Shortages are easing in 2025 and 2026, on pace for the fewest in about twenty years. The fragility underneath has not moved.
What it means
For you, the occasional empty shelf is a symptom, not an accident, and it will keep recurring until the upstream chemistry has more than one home. For the system, the real test is never the blockbuster everyone watches. It is the dollar vial of chemo that only one plant still makes.
Your Billing Process Is Slower Than You Think
Most SaaS finance teams underestimate how much billing lag is costing them.Most SaaS finance teams underestimate how much billing lag is costing them.
The Tabs Billing Lag Calculator benchmarks your process against top SaaS companies and puts a dollar figure on the gap — in two minutes.
